Home > Resources > Whitepapers > Particle characterisation of pharmaceutical powder mixtures

Particle characterisation of pharmaceutical powder mixtures

One of the most important performance factors of a pharmaceutical product is the bioavailability, i.e. the release of the active compound in a human body. In a solid dosage product (e.g. tablets, powders or capsules), this is directly related to the dissolution rate, which in turn is a function of particle size. In a raw material, mainly found as powder samples, it is essential to determine the particle size and size distribution. During the pharmaceutical development, multiple ingredients are mixed. Therefore, it is critical to monitor particle size, size distribution and spatial distribution of these compounds in the intermediate/final products. Less than optimized processing, for example too little or too much mixing, can lead to agglomerates and uneven distribution, which can result in a poor content uniformity, a heterogeneity in the product, or an undesirable dissolution rate profile.

I'm For Real

Enter your details once to access all our information and resources

Spotlight

Drugs & Diagnostics for Tropical Diseases

Our mission is to develop treatments and diagnostics for neglected tropical diseases that affect the most impoverished social groups. An urgent gap in treatment technology has left millions in sub-Saharan Africa at risk of debilitating and deadly parasitic diseases--but we're developing a novel diagnostic device that will end this. There is an urgent need for a simple, rapid, and quantitative diagnostic test to detect loiasis, an infection of the parasitic roundworm Loa loa (L. loa). Even though treatments exist, there are no commercial diagnostic tests available to identify the disease and monitor treatment efficacy.

OTHER WHITEPAPERS
news image

2020 Prescription Drug List

whitePaper | April 7, 2020

The information in this document is designed to help you understand the prescription drug benefits offered under this plan and to compare these benefits to those offered by other plans. Information contained in this summary is designed to help you compare both the value and scope offormulary benefits.

Read More
news image

Deal-Making Roundup

whitePaper | November 19, 2022

In the second year of the pandemic, dealmaking continued to take place at record levels, maintaining much of the momentum created during 2020.

Read More
news image

Pharmaceutical Sales Strategies Post-COVID-19: The Benefits of Virtual Engagement

whitePaper | April 7, 2021

In less than a week, in the face of a pandemic, the pharmaceutical sales model changed forever. In-person healthcare provider (HCP) visits came to a screeching halt and brand marketers scrambled to find ways to educate and engage these providers remotely. While the pandemic may have taken us by surprise, we should acknowledge that, even before the pandemic, pharmaceutical sales teams faced significant challenges. One solution for these challenges is to engage HCPs – virtually.

Read More
news image

Essential for Stable U.S. Supply Chains of Quality Pharmaceuticals

whitePaper | May 11, 2022

CDER is taking another step towards realizing the vision for pharmaceutical quality in the 21st century: a maximally efficient, agile, flexible manufacturing sector that reliably produces high-quality drug products without extensive regulatory oversight.

Read More
news image

DEVELOPING AND OPTIMIZING CLEANING PROCESSES

whitePaper | November 1, 2022

Equipment cleaning in manufacturing companies is often not given the same emphasis as other processes. It can be viewed as a task.

Read More
news image

Starting Materials For Homeopathic Drug Products

whitePaper | December 31, 2021

The scope of this white paper includes GMPs relevant for mass manufacturing/batch53 processing of products intended for widescale retail marketing. Starting materials and 54 packaging components for drug products

Read More

2020 Prescription Drug List

whitePaper | April 7, 2020

The information in this document is designed to help you understand the prescription drug benefits offered under this plan and to compare these benefits to those offered by other plans. Information contained in this summary is designed to help you compare both the value and scope offormulary benefits.

Read More

Deal-Making Roundup

whitePaper | November 19, 2022

In the second year of the pandemic, dealmaking continued to take place at record levels, maintaining much of the momentum created during 2020.

Read More

Pharmaceutical Sales Strategies Post-COVID-19: The Benefits of Virtual Engagement

whitePaper | April 7, 2021

In less than a week, in the face of a pandemic, the pharmaceutical sales model changed forever. In-person healthcare provider (HCP) visits came to a screeching halt and brand marketers scrambled to find ways to educate and engage these providers remotely. While the pandemic may have taken us by surprise, we should acknowledge that, even before the pandemic, pharmaceutical sales teams faced significant challenges. One solution for these challenges is to engage HCPs – virtually.

Read More

Essential for Stable U.S. Supply Chains of Quality Pharmaceuticals

whitePaper | May 11, 2022

CDER is taking another step towards realizing the vision for pharmaceutical quality in the 21st century: a maximally efficient, agile, flexible manufacturing sector that reliably produces high-quality drug products without extensive regulatory oversight.

Read More

DEVELOPING AND OPTIMIZING CLEANING PROCESSES

whitePaper | November 1, 2022

Equipment cleaning in manufacturing companies is often not given the same emphasis as other processes. It can be viewed as a task.

Read More

Starting Materials For Homeopathic Drug Products

whitePaper | December 31, 2021

The scope of this white paper includes GMPs relevant for mass manufacturing/batch53 processing of products intended for widescale retail marketing. Starting materials and 54 packaging components for drug products

Read More
More Whitepapers

Spotlight

Drugs & Diagnostics for Tropical Diseases

Our mission is to develop treatments and diagnostics for neglected tropical diseases that affect the most impoverished social groups. An urgent gap in treatment technology has left millions in sub-Saharan Africa at risk of debilitating and deadly parasitic diseases--but we're developing a novel diagnostic device that will end this. There is an urgent need for a simple, rapid, and quantitative diagnostic test to detect loiasis, an infection of the parasitic roundworm Loa loa (L. loa). Even though treatments exist, there are no commercial diagnostic tests available to identify the disease and monitor treatment efficacy.

Events

National Medtech & Biotech Summit 2024

Conference